Paragon Biosciences LLC — 2021 Investments

1 investments dated 2021 · listed companies and verified rows first · show all

Emalexemalex.com 𝕏Mar 2021 · $35M✓ verified

Emalex Biosciences is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, with a lead investigational asset, ecopipam, a selective dopamine D1 receptor antagonist for pediatric Tourette syndrome.

BiotechDigital Health

Co-investorsValor Equity Partners Bain Capital Life Sciences Fidelity Investments

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.